About NEOGAP
NEOGAP is a company based in Stockholm (Sweden) founded in 2016.. NEOGAP has raised $472.98 thousand across 3 funding rounds from investors including Okomera, European Union and Eureka Network. NEOGAP offers products and services including pTTL Cell Therapy, PIOR® Technology, and EpiTCer® Technology. NEOGAP operates in a competitive market with competitors including Moderna, BeiGene, Incyte, MorphoSys and Annexon, among others.
- Headquarter Stockholm, Sweden
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Neogap Therapeutics Ab
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$472.98 K (USD)
in 3 rounds
-
Latest Funding Round
$472.98 K (USD), Seed
Mar 26, 2024
-
Investors
Okomera
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NEOGAP
NEOGAP offers a comprehensive portfolio of products and services, including pTTL Cell Therapy, PIOR® Technology, and EpiTCer® Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Personalized therapy that trains immune cells to target cancer cells.
Platform for identifying tumor-specific mutations in cancer research.
Technology for manufacturing cell therapies targeting neoantigens.
Funding Insights of NEOGAP
NEOGAP has successfully raised a total of $472.98K across 3 strategic funding rounds. The most recent funding activity was a Seed round of $472.98 thousand completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Seed — $472,984
-
First Round
First Round
(01 Jun 2023)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2024 | Amount | Seed - NEOGAP | Valuation | Okomera | |
| Nov, 2023 | Amount | Grant - NEOGAP | Valuation |
investors |
|
| Jun, 2023 | Amount | Grant - NEOGAP | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in NEOGAP
NEOGAP has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Okomera, European Union and Eureka Network. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Founded Year | Domain | Location | |
|
Microfluidic chip device for in vitro cancer testing is developed.
|
Founded Year | Domain | Location | |
|
Business management consulting services are offered to clients.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by NEOGAP
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - NEOGAP
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Neogap Comparisons
Competitors of NEOGAP
NEOGAP operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, MorphoSys and Annexon, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
ALX Oncology is focused on advancing cancer treatment therapies.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Neogap
Frequently Asked Questions about NEOGAP
When was NEOGAP founded?
NEOGAP was founded in 2016 and raised its 1st funding round 7 years after it was founded.
Where is NEOGAP located?
NEOGAP is headquartered in Stockholm, Sweden.
Is NEOGAP a funded company?
NEOGAP is a funded company, having raised a total of $472.98K across 3 funding rounds to date. The company's 1st funding round was a Grant of $8.87M, raised on Jun 01, 2023.
What does NEOGAP do?
NEOGAP was founded in 2016 in Stockholm, Sweden, within the biotechnology sector focused on oncology. Radiopharmaceuticals are developed for cancer treatment, including the pTTL cell therapy product. Neoantigens are targeted through proprietary PIOR technology and patented EpiTCer methods. Immune cells sourced from cancer patients serve as the starting material for these therapies. Operations emphasize personalized approaches to enhance treatment efficacy.
Who are the top competitors of NEOGAP?
NEOGAP's top competitors include Moderna, BeiGene and Strand Therapeutics.
What products or services does NEOGAP offer?
NEOGAP offers pTTL Cell Therapy, PIOR® Technology, and EpiTCer® Technology.
Who are NEOGAP's investors?
NEOGAP has 4 investors. Key investors include Okomera, European Union, Eureka Network, and EIC Fund.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.